A Novel Intervention for Weight Loss in Young Adults
University of Chicago · with Northwestern University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06230744
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–40 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 140
- US sites recruiting
- 1
- Study start
- September 10, 2024
- Record last updated
- October 1, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Obesity and cardiometabolic risks are significant public health issues, with about two-thirds of U.S. adults overweight or obese. Weight loss can prevent these health problems, but current lifestyle interventions have limited success. New, effective strategies are needed to address this rising issue at the population level. The goal of this clinical trial is to investigate how a behavioral intervention combined with technology impacts weight loss in young adults. The main questions it aims to answer are:
- How does the combination of behavioral intervention and technology influence weight loss in young adults?
Being studied: Lifestyle; Lifestyle II
Conditions: Weight Loss
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Overweight or obese (BMI 25.5- 34.9 kg/m2) men and women
- Ages 18 to 40 years
- Weight stable (no change >25 lbs in the past 3 months)
- Owns a smartphone and willing to install the study app
Exclusion Criteria
- Presence of obstructive sleep apnea or history of any other sleep disorder.
- Irregular menses, menopausal symptoms or post-menopausal, currently pregnant, trying to get pregnant or nursing
- Regular travel across time zones
- Subjects who are currently following a weight loss regimen or any other special diet or exercise programs
- Increased fractional lean body mass (e.g., athletes)
- Unable to walk, using an assistive device for mobility, or any contraindications to exercise
- Diabetes
- Claustrophobia
- Excessive alcohol (>2 drinks/day) or caffeine (>300mg/day) intake, regular nicotine use, substance abuse.
- Abnormal findings on screening blood testing.
- Participants taking any prescription, over-the-counter drugs/supplements that can affect sleep or weight.
- Major psychiatric or any eating disorder, and any acute or chronic medical condition that increase the risk of interventions (e.g., heart disease)
- Any underlying disease likely to limit life span and/or increase risk of interventions including cardiovascular disease (e.g. unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, NYHA Class>2), pulmonary disease with dependence on oxygen or daily use of bronchodilators, cancer requiring treatment in the past 5 years unless the prognosis is considered good, active or chronic infection, thyroid disease and other endocrine disorders (e.g. Cushing syndrome, acromegaly), hepatitis or other chronic gastrointestinal disease (pancreatitis, inflammatory bowel disease), renal disease, significant anemia, recent surgery or significant abdominal surgery, major psychiatric or any eating disorder, acute coronary syndrome or stroke in the past 6 months
Recruiting US locations
University of Chicago
Chicago, IL 60637
Site contact: UChicago IRB · 773-702-6505
Study contacts (from the official record)
- Olivia Hughes · 7737022348 · bhughes8@bsd.uchicago.edu
Similar studies in Illinois
All weight loss studies in Illinois →- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Skokie, IL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Chicago, IL + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Alveus Therapeutics, Inc.
- Location
- Champaign, IL + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
Boston Scientific Corporation
- Location
- Chicago, IL + 8 other US sites
- Eligibility basics
- Ages 18+